{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"48.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug. Participants will be analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Percentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}